Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05384587
Title Asciminib Monotherapy, With Dose Escalation, for 2nd Line Chronic Myelogenous Leukemia (ASC2ESCALATE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST